All Comments by Dave Morgan

  1. Bapineuzumab Phase 3: Target Engagement, But No Benefit
  2. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.
  3. Smuggling Antibodies to BACE Across the Blood-Brain Barrier
  4. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.
  5. Piping in Passive Immunization Spares Blood Vessels
  6. Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy.
  7. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.
  8. Immunotherapy reduces vascular amyloid-beta in PDAPP mice.
  9. Complement: AD Friend or Foe? New Work Tips Balance to Former
  10. AD Immunotherapy: Toward Prevention, DNA-based Vaccines?
  11. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta.
  12. Incidence and prognosis of transient neurological attacks.
  13. Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease.
  14. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.
  15. San Diego: Treating Forgetfulness—Triple Transgenics Provoke